Navigation Links
Coyote Pharmaceuticals Initiates GMP Manufacturing Process for CNS-102 Following Successful Pre-IND Meeting
Date:2/13/2013

MENLO PARK, Calif., Feb. 13, 2013 /PRNewswire/ -- Coyote Pharmaceuticals, Inc., an emerging biopharmaceutical company focused on neurodegenerative diseases, announced today that it has initiated the GMP manufacturing process for CNS-102 following its recent pre-IND meeting with the Food and Drug Administration (FDA).  CNS-102 is being developed initially to treat amyotrophic lateral sclerosis (ALS).

In its meeting with the FDA, Coyote was advised to apply for Fast Track designation when it submits its Investigational New Drug (IND) application for CNS-102 for the treatment of ALS.  Coyote expects to file its IND in the fourth quarter of 2013 and commence a Phase 1 clinical study of CNS-102 in early 2014.

"Initiating the GMP manufacturing process for CNS-102 signals the first step in our clinical development program for ALS and follows a successful meeting with the FDA in which we were advised to seek Fast Track designation for CNS-102 in ALS," commented Hiroaki Serizawa , Ph.D., president, CEO & co-founder of Coyote Pharmaceuticals.  "Given that Fast Track designation is not typically discussed until Phase 2 data is produced, we view the FDA's position as very encouraging for our technology and strategy of targeting heat shock protein induction as a potential treatment for ALS."

According to the FDA, Fast Track designation is intended to facilitate the development and expedite the review of drugs to treat serious diseases and fill an unmet medical need.  The purpose is to get important new drugs to the patient earlier.  Most drugs eligible for Fast Track designation are likely to be considered appropriate to receive a Priority Review.  A Priority Review means that the time it takes FDA to review a new drug application is reduced.  The goal for completing a Priority Review is six months.

About Coyote Pharmaceuticals:
Coyote Pharmaceuticals, Inc. is an emerging biopharmaceutical company focused on treating neurodegenerative diseases through the mitigation of protein misfolding and pathological protein aggregation.  The company's lead drug candidate, CNS-102, is being developed initially to treat amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD).  The orally bioavailable small molecule therapeutic is designed to activate gene expression of a family of proteins – known as heat shock proteins – which have evolved to regulate the folding and intracellular transport of other proteins. Heat shock proteins are capable of preventing and repairing the pathophysiological aggregation of several proteins that have been implicated in the etiology of ALS and AD.  For more information on Coyote visit http://www.coyotepharma.com.

For Media & Investors:
Jason Rando / Joshua Drumm , Ph.D.
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jrando@tiberend.com 
jdrumm@tiberend.com


'/>"/>
SOURCE Coyote Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Founder of Nestle-Acquired Company Joins Prismic Pharmaceuticals
2. RQx Pharmaceuticals and Genentech Enter Drug Discovery Collaboration to Develop Novel Drug Compounds
3. Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results
4. Jazz Pharmaceuticals To Report 2012 Fourth Quarter And Full Year Financial Results On February 26, 2013
5. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
6. Perrigo Company Acquires U.K.-based Rosemont Pharmaceuticals Ltd. For Approximately £180 Million Or $283 Million
7. Inovio Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
8. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
9. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
10. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
11. Shares of Oramed Pharmaceuticals Are Approved for Listing on the Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
Breaking Medicine News(10 mins):